Sight Sciences, Inc. (SGHT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$9.68+2.76%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · SGHT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 32.2% |
| Our one-year growth estimate | diamond | 17.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 14.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
SGHT — General Counsel transition
Dated 2026-08-10
Chief Legal Officer — Kashif Rashid: The company appointed an external candidate to fill the Chief Legal Officer role, which is a standard executive hiring event rather than a departure.
Why it matters: Q2 revenue grew 20% year over year. Another increase would support the raised 2026 revenue range of $88 million to $92 million.
Supportive ifQ3 revenue tops $23.4 million, the Q2 2026 result, and management keeps its $88 million to $92 million full-year range.
Worry ifQ3 revenue is below $23.4 million, or management cuts the $88 million to $92 million full-year range.
Why it matters: Q2 set a sales record, and new fee schedules added about 4.1 million covered lives. More growth would show these gains are reaching patients.
Supportive ifQ3 Interventional Dry Eye revenue tops $2.7 million. Sales grow after the added fee schedules.
Worry ifQ3 Interventional Dry Eye revenue is $2.7 million or less. Or, the company says added coverage has not led to more sales.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$165 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $657 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,188 loss on $10,000 · 61.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.